Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 367,406 shares of the specialty pharmaceutical company’s stock after selling 14,088 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.14% of Collegium Pharmaceutical worth $10,526,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC boosted its position in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the last quarter. KBC Group NV boosted its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $72,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares during the last quarter.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now directly owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock worth $3,243,594 over the last three months. Company insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on COLL shares. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Up 0.4 %

Shares of COLL opened at $30.05 on Friday. The firm has a market cap of $946.15 million, a P/E ratio of 12.95 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The company’s 50-day moving average price is $30.69 and its 200 day moving average price is $32.67. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.